Champions Oncology Q1 Earnings Call Highlights

Key Points

• Revenue and profitability improved: First-quarter fiscal 2027 revenue rose 9% to $15.2 million, while adjusted EBITDA increased to $671,000 from $59,000, marking the company’s fifth consecutive positive quarter.
• Services margins expanded: Translational oncology services revenue reached $14.3 million, and its margin improved to 51% from 43%, driven by lower third-party radiolabeling costs and operating leverage.
• Data licensing gained momentum: Data revenue reached $893,000, exceeding the full fiscal 2026 total, although management cautioned that quarterly results may remain uneven. Champions ended the quarter with $4.4 million in cash and no debt while continuing discussions around potential Corellia funding or licensing.

Champions Oncology NASDAQ: CSBR reported first-quarter fiscal 2027 revenue growth, improved margins and its fifth consecutive quarter of positive adjusted EBITDA, as both its translational oncology services and data licensing businesses contributed to results.

Revenue for the quarter totaled $15.2 million, up approximately 9% from $14.0 million in the prior-year period. The company reported a GAAP net loss of approximately $426,000, compared with a net loss from operations of $527,000 a year earlier. Adjusted EBITDA rose to $671,000 from $59,000 in the prior-year quarter.

“The first quarter is a strong data point that we are moving in the right direction,” Chief Executive Officer Rob Brainin said. He described fiscal 2026 as an investment year and said the company is focused on demonstrating that those investments are producing revenue, margin and data-business progress during fiscal 2027.

Services Revenue and Margin Improvement

Champions Oncology’s translational oncology services business generated $14.3 million of revenue during the quarter. Brainin said demand for the company’s predictive modeling work remained healthy, adding that the quality of its tumor bank continues to be an important factor for customers.

The company’s oncology services margin increased to 51% from 43% in the prior-year quarter. Chief Financial Officer David Miller said cost of oncology revenue declined to approximately $7.5 million from $8.0 million a year ago despite higher revenue. He attributed the reduction primarily to lower third-party radiolabeling costs as the company brings those capabilities in-house.

Miller also said higher revenue contributed to the margin expansion through operating leverage. He noted that improved sales quality over recent quarters resulted in a higher percentage of contracted study value converting to first-quarter revenue, a trend that continued with sales made during the quarter.

Data Licensing Exceeds Prior Full-Year Level

Data licensing revenue was $893,000 in the first quarter, exceeding the amount Champions Oncology generated from data revenue during all of fiscal 2026, according to Brainin. He said the performance reflected a broader customer base developed over the last year.

Management cautioned that data licensing revenue is likely to remain uneven from quarter to quarter because contracts close on their own timelines. Still, Brainin said the pipeline remains robust and the strategic rationale for the business is strengthening as drug developers increasingly use artificial intelligence and machine learning in development decisions.

“The constraint isn't the model, it's the data underneath it,” Brainin said, pointing to the company’s clinically annotated, patient-derived data. He said the data business could help sponsors identify signatures, select patients and design trials, rather than only predict the results of individual studies.

Expenses, Cash and Corellia Discussions

Research and development expense declined to $1.9 million from $2.1 million in the prior-year period. Miller said the company reduced spending in its core services business while redirecting resources toward its Corellia therapeutic subsidiary and data initiatives.

Sales and marketing expense increased to $3.0 million from $1.8 million a year earlier, reflecting a deliberate investment in expanding the commercial organization across research services and data businesses. General and administrative expense was essentially unchanged at approximately $2.1 million.

Champions Oncology used approximately $500,000 of cash during the quarter, primarily due to ordinary working-capital movements, including lower accounts payable and higher accounts receivable. The company ended the period with approximately $4.4 million in cash and no debt.

Brainin said external discussions regarding Corellia continue with venture groups and potential pharmaceutical partners. He did not provide a timetable for a funding or licensing outcome. If outside funding or a licensing partnership is secured, he said investment currently directed to Corellia could be redeployed to other growth initiatives, particularly the data business, and to the company’s bottom line.

Management said it intends to maintain expense discipline while pursuing revenue growth and improved profitability through the remainder of fiscal 2027.

About Champions Oncology (NASDAQ:CSBR)

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.